OTEZLA XR
Live / Applied — First extension granted (statement of use) (as of 03 Sept 2025)
What this means for you
Not registered yet, but its 05 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98682726
- Mark type
- Design + words
- Filed
- 05 Aug 2024
- Published for opposition
- 28 Jan 2025
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of chronic inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis and cancer
Owner
- Amgen Inc., Thousand Oaks, CA, US
- Amgen Inc., Thousand Oaks, CA, US
Prosecution history
- 31 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Sept 2025 — SOU EXTENSION 1 GRANTED
- 03 Sept 2025 — SOU EXTENSION 1 FILED
- 03 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Jan 2025 — PUBLISHED FOR OPPOSITION
- 22 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Jan 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 02 Jan 2025 — NOTICE OF REVIVAL - E-MAILED
- 02 Jan 2025 — PETITION TO REVIVE-GRANTED